Company News Hub
Cambridge Epigenetix News
No direct newsroom story is tagged to Cambridge Epigenetix yet. Use this page with the linked company profile and hub routes to keep the chronology tied to the broader market context.
Coverage Snapshot: Cambridge Epigenetix
Cambridge Epigenetix is currently mapped as a Startup company at the Series D stage, with operating context centered on London, England, United Kingdom. The company summary on this route is: Cambridge Epigenetix is using epigenetics to reduce diagnostic tests for common cancers to a simple blood draw. Biotech Healthcare Medical
What's Already Mapped
- Funding context: $88.00M, latest mapped round Series D (Sequoia, $88M Series D in 2021, $350M valuation).
- Founder coverage: Cambridge Epigenetix Team
- Market lens: Startup | Series D | London, England, United Kingdom.
- Hiring watch: active role clusters include Open Roles.
Connected Routes
Related topics
Use the story feed below for chronology, then bounce back to the company profile and hub pages when you need peer, geography, or stage-level comparison.
No direct newsroom stories yet
We have not mapped a direct tagged article to Cambridge Epigenetix yet. In practice, that usually means the coverage is currently showing up inside broader startup or market-wide stories rather than on a single company-specific route.
- Start with the company profile for the cleanest summary of current company data.
- Check United Kingdom newsroom for geography-specific momentum.
- Compare peers through Startup startup pages and Series D funding coverage.